|
| |
Takeda Pharmaceuticals North America, Inc.Takeda Pharmaceuticals North America, Inc. is a new kind of pharmaceutical company. We are dedicated to serving patients by providing innovative products that improve their lives with better healthcare. With a foundation built on the tremendous success of ACTOS® (pioglitazone HCl) as well as a robust, early-stage pipeline, TPNA is poised to realize its vision of becoming a world class pharmaceutical company. Our unique culture sets us apart. At TPNA, we are committed to patients, our employees and the community. We have an innovative, entrepreneurial spirit combined with the rich history of our 220-year-old parent company.
Headquartered in Lincolnshire, Illinois, a northern suburb of Chicago, TPNA is a wholly owned U.S. subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company. With more than five years of service in the U.S., we have grown rapidly and each step of that growth remains true to the company’s integrity, heritage and people.
| Contact Details: |
| 475 Half Day Road |
| Lincolnshire |
| Illinois |
| 60069 |
| United States of America |
| Tel: | 847-383-3000 |
| Fax: | |
| Email: | pr@tpna.com |
| WWW: | www.tpna.com/
|
|
Loading...
|
Press Releases on Takeda Pharmaceuticals North America, Inc.:
|
 |
| Video: Novartis Launches Prevacid(R)24HR Over-the-Counter for Full 24-Hour Frequent Heartburn Treatment |
12th November, 2009 |
Novartis Consumer Health |
-- For 52% of sufferers, discomfort from frequent heartburn has some impact
on their work, including their ability to focus in meetings and their
overall ability to be productive.
|
| Takeda Establishes Takeda Pharmaceuticals Mexico, S.A. de C.V. Expanding Presence in North America |
3rd November, 2009 |
Takeda Pharmaceuticals North America, Inc. |
DEERFIELD, Ill., Nov. 3 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the
|
| Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009 |
27th October, 2009 |
Cephalon, Inc. |
FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7
|
| New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD |
26th October, 2009 |
Takeda Pharmaceuticals North America, Inc. |
SAN DIEGO, Oct. 26 /PRNewswire/ -- New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM)
|
| ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout |
17th October, 2009 |
Takeda Pharmaceuticals North America, Inc. |
-- ULORIC is contraindicated in patients being treated with azathioprine,
mercaptopurine, or theophylline.
-- An increase in gout flares is frequently observed during
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 467 times since April 2007, the link to the organisation's website has been followed 85 times Recent Search Terms used to find this page: tpna quote | TPNA Services nashville | . Search for more companies in Lincolnshire Search for more companies in Illinois This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Takeda Pharmaceuticals North America, Inc. |
